We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ENOB market cap is 106.2M. The company's latest EPS is USD -0.5468 and P/E is -1.59.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.27M | -17.19M | -51.3M | -53.34M | -4.55M |
| Net Income | -4.53M | -17.03M | -57.7M | -44.21M | -7.25M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.92M | -23.4M | -22.83M | -38.56M | -81.64M |
| Net Income | -11.42M | -26.97M | -113.43M | -39.68M | -80.65M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 58.02M | 212.28M | 163.13M | 121.83M | 111.34M |
| Total Liabilities | 14.42M | 43.68M | 31.15M | 23.75M | 29.28M |
| Total Equity | 43.6M | 168.6M | 131.98M | 98.09M | 82.06M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 178.1M | 189.61M | 84.63M | 58.3M | 163.13M |
| Total Liabilities | 11.83M | 14.94M | 12.01M | 11.8M | 31.15M |
| Total Equity | 166.27M | 174.66M | 72.62M | 46.5M | 131.98M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -5.92M | -8.56M | -10.97M | -2.02M | -4.58M |
| Investing | -1.12M | -1.21M | -1.26M | N/A | N/A |
| Financing | 5.41M | 8.05M | 10.52M | 2.03M | 4.62M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -10.46M | -20.61M | -15.73M | -11.78M | -10.97M |
| Investing | -185k | -49k | -5k | -30k | -1.26M |
| Financing | 7.2M | 32.6M | 4.25M | 4.52M | 10.52M |
| Market Cap | 106.2M |
| Price to Earnings Ratio | -1.59 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 580 |
| Price to Book Ratio | 0.97 |
| Dividend Yield | - |
| Shares Outstanding | 147.51M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.06 (7.53%) |
| Company Name | Enochian Biosciences Inc |
| Address |
108 w. 13th street suite 100 wilmington, delaware 19801 |
| Website | https://renovarobio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
